Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study

Wang, Qiuhe; Xia, Dongdong; Bai, Wei; Wang, Enxin; Sun, Jun‐Hui; Huang, Ming; Mu, Wei; Yin, Guowen; Li, Hailiang; Zhao, Hui; Li, Jing; Zhang, Chunqing; Zhu, Xiaoli; Wu, Jianbing; Li, Jiaping; Gong, Weidong; Li, Zixiang; Lin, Zhong‐Zhe; Pan, Xingnan; Shi, Haibin; Shao, Guoliang; Liu, Jueshi; Yang, Shufa; Zheng, Yanbo; Xu, Jingyi; Song, Jukun; Wang, Wenhui; Wang, Zhexuan; Zhang, Yuelin; Ding, Rong; Zhang, Hui; Yu, Hui; Lin, Zheng; Gu, Weiwei; You, Nan; Wang, Guangchuan; Zhang, Shuai; Lin, Feng; Liu, Lin; Zhang, Peng; Li, Xueda; Chen, Jian; Xu, Tao; Zhou, Wei-Zhong; Zhou, Hui; Zhang, Yongjin; Huang, Weijian; Jiang, Wenjin; Zhang, Wen; Shao, Wenbo; Li, Lei; Niu, Jing; Yuan, Jie; Li, Xiaomei; Lv, Yong; Li, Kai; Yin, Zhihua; Xia, Jielai; Fan, Daiming; Han, Guohong

doi:10.1016/j.jhep.2019.01.013

Cited by 194 publications

(210 citation statements)

References 55 publications

Supporting

Mentioning

193

Contrasting

Unclassified

Order By: Relevance

“…Our study showed that the presence of hypovascular hepatic nodules with intermediate‐stage HCC, which is not targeted for TACE, on pretreatment dynamic imaging represents a significant predictive risk factor for TACE refractoriness. Numerous previous studies have investigated useful predictors of the response to TACE and classifications related to baseline tumors to estimate the prognosis after TACE . However, the clinical significance of hypovascular hepatic nodules coexisting with intermediate‐stage HCC for predicting TACE refractoriness has never been verified.…”

Section: Discussionmentioning

confidence: 99%

“…Patients with intermediate‐stage HCC represent a highly heterogeneous population with differences in tumor size, tumor number, histological differentiation, vascularity, and liver function; thus, the clinical benefits of TACE are variable . Researchers have attempted to categorize this population into subgroups, and establish useful predictors based on prognostic models and scores.…”

Section: Discussionmentioning

confidence: 99%

“…The present study also found that the TTTR was significantly shorter for patients out of the up‐to‐seven criteria than that for the other patients. Other subgrouping risk predictors, such as tumor number alone and other scoring systems (the maximum tumor diameter plus tumor number, and tumor factors plus laboratory values), have been proposed to identify ideal candidates for TACE . Although these risk predictors were constructed based on the characteristics of viable lesions targeted for TACE treatment, the present study focused on inactive lesions not targeted for TACE treatment.…”

Section: Discussionmentioning

confidence: 99%

“…O UR STUDY SHOWED that the presence of hypovascular hepatic nodules with intermediatestage HCC, which is not targeted for TACE, on pretreatment dynamic imaging represents a significant predictive 30,31 Researchers have attempted to categorize this population into subgroups, and establish useful predictors based on prognostic models and scores. Bolondi et al…”

Section: Discussionmentioning

confidence: 99%

“…Other subgrouping risk predictors, such as tumor number alone and other scoring systems (the maximum tumor diameter plus tumor number, and tumor factors plus laboratory values), have been proposed to identify ideal candidates for TACE. 11,30,31 Although these risk predictors were constructed based on the characteristics of viable lesions targeted for TACE treatment, the present study focused on inactive lesions not targeted for TACE treatment. Our results revealed another useful predictor, hypovascular hepatic nodules, based on different concepts from previous classifications and predictors.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma

Maesaka

Sakamori

Yamada

et al. 2019

Hepatology Research

View full text Add to dashboard Cite

Aim Intermediate‐stage hepatocellular carcinoma (HCC) targeted for transcatheter arterial chemoembolization (TACE) corresponds to a highly heterogeneous population for whom the factors predicting TACE efficacy have not been established. This study aimed to evaluate the impact of hypovascular hepatic nodules coexisting with intermediate‐stage HCC as a significant predictive factor for TACE refractoriness. Methods A total of 66 patients with intermediate‐stage HCC who received initial TACE were retrospectively analyzed. Hypovascular hepatic nodules were detected by dynamic computed tomography or magnetic resonance imaging, as well as angiography, before all initial TACE. The time to TACE refractoriness (TTTR) was defined as the period from initial TACE until the diagnosis of TACE refractoriness. Results Hypovascular hepatic nodules were detected in 36 patients (54.5%), 15 (41.7%) of whom had a single nodule, whereas 21 (58.3%) had multiple nodules, and the median size of the maximum nodule was 10 mm (range 5–80 mm). The median TTTR was 17.4 months for all patients, and 7.3 and 33.1 months for patients with and without hypovascular hepatic nodules, respectively. The TTTR was significantly shorter for patients with hypovascular hepatic nodules than that for the other patients. In the multivariate analysis, the presence of hypovascular hepatic nodules (HR 7.016, 95% CI 3.534–13.930; P < 0.001) and being out of the up‐to‐seven criteria (HR 2.861, 95% CI 1.493–5.486; P = 0.002) were independent risk factors for a short TTTR. Conclusions The presence of hypovascular hepatic nodules with intermediate‐stage HCC represents a significant predictive risk factor for TACE refractoriness.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma

Maesaka

Sakamori

Yamada

et al. 2019

Hepatology Research

View full text Add to dashboard Cite

show abstract

Oncofetal MCB1 Is a Functional Biomarker for HCC Personalized Therapy

Xiang,

Liu,

Wang

et al. 2024

Advanced Science

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer‐related death worldwide and lacks biomarkers for personalized therapy. Herein, it is reported that MCB1 could be a novel oncofetal protein that is upregulated in the preneoplastic lesions and serum of early HCC patients. Functional studies reveal that MCB1 modulated p53 protein degradation to promote T‐IC generation and drive HCC initiation. Furthermore, the MCB1/p53 axis is shown to determine the responses of hepatoma cells to conventional chemotherapeutics and predict transcatheter arterial chemoembolization (TACE) benefits in patients. Importantly, MCB1 can mediate sorafenib/lenvatinib resistance by downregulating two essential drug targets fibroblast growth factor receptor 1 (FGFR1) and vascular endothelial growth factor receptor 3 (VEGFR3) expression in a proteasome‐dependent manner. Patient‐derived tumor organoids (PDOs), patient‐derived xenografts (PDXs), and patient cohorts analysis suggested that MCB1 levels in HCCs may determine the distinct responses to conventional therapeutics and targeted drugs. Furthermore, treatment of targeted drugs‐resistant HCC with adeno‐associated virus (AAV) targeting MCB1 or a proteasome inhibitor restores targeted drug response, suggesting their clinical significance in HCC combinational therapy. In conclusion, these findings demonstrate that MCB1 could act as a driver for HCC initiation, a contributor to drug resistance, and a biomarker for individualized HCC therapy.

show abstract

Long‐term outcomes in patients with advanced adrenocortical carcinoma after image‐guided locoregional ablation or embolization

et al. 2021

View full text Add to dashboard Cite

show abstract

Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study

Cited by 194 publications

References 55 publications

Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma

Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma

Oncofetal MCB1 Is a Functional Biomarker for HCC Personalized Therapy

Long‐term outcomes in patients with advanced adrenocortical carcinoma after image‐guided locoregional ablation or embolization

Contact Info

Product

Resources

About